Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered

Authors: Filippo Sanfilippo, Luigi La Via, Federica Merola, Marinella Astuto

DOI: 10.5603/CJ.a2021.0078

Article type: Letter to the Editor

Submitted: 2021-04-25

Accepted: 2021-07-03

Published online: 2021-07-07

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered

Filippo Sanfilippo et al., Levosimendan for heart failure: more studies needed

Filippo Sanfilippo, Luigi La Via, Federica Merola, Marinella Astuto
Department of Anaesthesia and Intensive Care, A.O.U. Policlinico-San Marco, Catania, Italy

Address for correspondence: Filippo Sanfilippo, MD, PhD, Department of Anaesthesia and Intensive Care, A.O.U. Policlinico-San Marco, Catania, Italy, Via Santa Sofia, 78 – 95100 – Catania, Italy, tel: 0039 0953782307, fax: 0039 0953782673, e-mail: filipposanfi@yahoo.it

It is with great interest that we read the meta-analysis by Jaguszewski et al. [1] comparing the effects of levosimendan and dobutamine in patients with heart failure (HF). This meta-analysis is relevant and it confirms a possibly preferential role for levosimendan in this population of patients considering the significant reduction in hospital (or 30-day) mortality, as shown by the pooled analysis on the 10 included studies. This finding is not surprising, since this ino-dilator has shown a reduction in mortality for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery. Moreover, levosimendan also reduced the need for renal replacement therapy after high-risk cardiac surgery [2].

However, before drawing firm conclusions on the use of levosimendan in patients with HF, an analysis of the robustness of the findings by Jaguszewski et al. [1] is needed. Therefore, it was thought that the manuscript would greatly benefit from the addition of a trial-sequential analysis (TSA), which would allow calculation of the required sample (“information size”), estimating the power of the meta-analysis on the reduction of mortality by levosimendan, as well as the need for further research.

Hereby, we would like to offer a contribution. We imported the same data provided by the authors in the TSA Software (Copenhagen Trial Unit's TSA Software®; Copenhagen, Denmark). The information size was computed assuming an alpha risk of 5% with a power of 80%. The estimated mortality was computed using weighted averages from the included studies (levosimendan 8.4% vs. dobutamine 12.6%). We used a random effect model with mortality analyzed as odds ratio (OR). Further details on TSA and its interpretation are available elsewhere [3].

The TSA showed that current evidence is severely underpowered to determine whether levosimendan reduces mortality in patients with HF as compared to dobutamine. Indeed, the ratio between number of patients recruited and sample needed (n = 2263/8366; 27%; Fig. 1). Therefore, more research is certainly warranted on mortality in this population of patients.

Another minor (statistical) consideration is on the authors’ choice to perform their meta-analysis using a fixed effect model, which assumes that the true effect is the same across studies. However, it is unlikely that all included studies have “identical” true effect, especially when there is statistical heterogeneity (47% in the meta-analysis Jaguszewski et al. [1]). In such cases it is
advisable to use a random effect model, which better balances the weights of the included studies [4]. For instance, moving from the fixed to the random effect model, the weight of the largest study (Mebazaa et al. [5]) on the overall results passed from 62% to 28.6%. Nonetheless, our consideration does not change the meta-analysis results since levosimendan still shows significant reductions in mortality also using the random effect model (OR: 0.45; 95% confidence interval 0.24–0.84; p = 0.01).

In summary, in their meta-analysis Jaguszewski et al. [1] showed benefits of levosimendan over dobutamine for patients with HF with a significant reduction in hospital (or 30-day) mortality. However, current evidence is severely underpowered and further randomized research is required before drawing firm conclusions.

Conflict of interest: None declared

References


Figure 1. Trial sequential analysis on hospital (30-day) mortality in patients with heart failure (HF), comparing treatment with levosimendan versus dobutamine; RE — random effect; RR — risk reduction.
Levosimendan vs Dobutamine in HF - Mortality: RE, RR = 0.8366 in a Two-sided graph.